MyLungCancerTeam

The life expectancy for stage 4 lung cancer with a KRAS mutation is generally poor. KRAS mutations are associated with worse survival rates. For stage 4 non-small cell lung cancer (NSCLC), the five-year survival rate is about 7%. However, treatments like Lumakras, approved for KRAS G12C mutations, may improve outcomes Show Full Answer

The life expectancy for stage 4 lung cancer with a KRAS mutation is generally poor. KRAS mutations are associated with worse survival rates. For stage 4 non-small cell lung cancer (NSCLC), the five-year survival rate is about 7%. However, treatments like Lumakras, approved for KRAS G12C mutations, may improve outcomes. Individual prognosis depends on factors like overall health and response to treatment. Always consult your doctor for personalized guidance.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Stage 4 Lung Cancer: What To Expect | MyLungCancerTeam

Stage 3 Lung Cancer: What To Expect | MyLungCancerTeam